Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:4701

Official publication of the Indian Society of Nephrology
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (271 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  


 Article Access Statistics
    PDF Downloaded131    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


  Table of Contents  
Year : 2012  |  Volume : 22  |  Issue : 3  |  Page : 228-229

Post-transplant infections

1 Department of Nephrology and Clinical Transplantation, Dr. H. L. Trivedi Institute of Transplantation Sciences (ITS), Institute of Kidney Diseases and Research Centre (IKDRC), Ahmedabad, Gujarat, India
2 Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, Dr. H. L. Trivedi Institute of Transplantation Sciences (ITS), Institute of Kidney Diseases and Research Centre (IKDRC), Ahmedabad, Gujarat, India

Date of Web Publication20-Jul-2012

Correspondence Address:
P R Shah
Department of Nephrology and Clinical Transplantation Institute of Kidney Diseases and Research Center and Dr. H L Trivedi Institute of Transplantation Sciences (IKDRC ITS), Civil Hospital Campus, Asarwa, Ahmedabad 380 016, Gujarat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-4065.98775

Rights and Permissions

How to cite this article:
Shah P R, Kute V B, Gumber M R, Patel H V, Vanikar A V, Trivedi H L. Post-transplant infections. Indian J Nephrol 2012;22:228-9

How to cite this URL:
Shah P R, Kute V B, Gumber M R, Patel H V, Vanikar A V, Trivedi H L. Post-transplant infections. Indian J Nephrol [serial online] 2012 [cited 2022 Dec 5];22:228-9. Available from:


We read with interest the article "Post-transplant infections: An ounce of prevention". [1] We have encountered a few patients of new-onset diabetes mellitus after transplantation (NODAT) on tacrolimus-based immunosuppression with asymptomatic hepatitis C virus (HCV)/Cytomegalovirus (CMV) infection detected on polymerase-chain-reaction assays. It is unclear whether HCVRNA and CMVDNA should be done in all transplant recipients at initial diagnosis of NODAT to detect asymptomatic HCV/CMV infection with or without other known risk factors especially when NODAT incidence is usually high?

A meta-analysis of ten studies of 2502 patients found that anti-HCV positive patients were nearly four times more likely to have NODAT compared with uninfected individuals. [2] The relationship between HCV infection and NODAT may be heightened with tacrolimus versus cyclosporine-based immunosuppression CMV infection has also been reported to increase the risk of NODAT. [3] In one study, an asymptomatic CMV infection was associated with a lower median insulin release and a fourfold increased risk of NODAT. [4]

Also unclear is how CMV, BK polyomavirus, herpes simplex virus (HSV) infection and others should be monitored in patients who had undergone desensitization protocol with multidrug regimen?Desensitized patients receive more immunosuppression treatment, including rituximab, plasmapheresis, and anti-thymocyte globulin, compared with nonsensitized patients, which might increase the risk of infection (especially CMV and BK polyoma virus).

For all highly sensitized patients who received a kidney transplant, polymerase-chain-reaction assays for CMV, and polyomavirus BK were performed on whole-blood specimens monthly for the first 3-6 months after transplantation and then every 3 months until the end of the first post-transplant year, or whenever there is an unexplained rise in serum creatinine, and after treatment for acute rejection, with appropriate clinical features. The methods used for monitoring viral replication have been described previously. [5],[6],[7] A Cedars Sinai group monitored their desensitized patients by monthly CMV, Epstein-Barr virus, parvovirus B-19, and BK virus (BKV) testing. [7] Antiviral prophylaxis should be considered in patients treated with bortezomibas herpes zoster virus (HZV) infections are common, especially in cancer patients. Vaccination against HZV before bortezomib use should be contemplated in HZV-naÏve patients. Weekly monitoring of CMV antigenaemia should be performed in seropositive patients at risk of reactivation or disease. [7],[8],[9],[10]

Whether the pre-emptive approach would be optimum in low risk (D-/R-) recipients who had received blood transfusions pre-transplant? The risk of CMV infection is rare in solid organ transplants who are at risk for severe morbidity from CMV infection and who receive CMV reduced risk products. Two methods to supply CMV reduced risk products, which appear to have equal efficacy are: CMV seronegative cellular components (red cells, platelets) or leukoreduced components. Such facility may not be available in all hospitals.

  References Top

1.Jha V. Post-transplant infections: An ounce of prevention. Indian J Nephrol 2010;20:171-8.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant 2005;5:2433-40.  Back to cited text no. 2
3.Hjelmesaeth J, Midtvedt K, Jenssen T, Hartmann A. Insulin resistance after renal transplantation: Impact of immunosuppressive and antihypertensive therapy. Diabetes Care 2001;24:2121-6.  Back to cited text no. 3
4.Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Daibetologia 2004;47:1550-6.  Back to cited text no. 4
5.Toyoda M, Puliyanda DP, Amet N, Baden L, Cam V, Radha R, et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005;80:198-205.  Back to cited text no. 5
6.Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-51.  Back to cited text no. 6
7.Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am SocNephrol 2011;6:922-36.  Back to cited text no. 7
8.Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.  Back to cited text no. 8
9.Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211-25.  Back to cited text no. 9
10.Lemy A, Toungouz M, Abramowicz D. Bortezomib: A new player in pre- and post-transplant desensitization? Nephrol Dial Transplant 2010;25:3480-9.  Back to cited text no. 10

This article has been cited by
1 Authoręs reply
Jha, V.
Indian Journal of Nephrology. 2012; 22(3): 229-230


Print this article  Email this article


© Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07